
Don't let summer solstice steal your sleep this weekend — how to fall asleep fast even when it's still sunny outside
Here are tips to avoid this and save your sleep this weekend:
Sunlight exposure during the day (and particularly in the morning) increases your cortisol levels, helping to keep you alert and active and can help with melatonin (the sleepy hormone) production at night (when melatonin is naturally released in response to darkness).
This process helps regulate your body's circadian rhythm (sleep and wake cycle), which means you're waking and falling asleep at the right times, and getting a restorative night's sleep.
However, continued exposure to bright light in the evening can confuse your brain into remaining stimulated, which can be counterproductive for your sleep at night.
With sunlight lasting until beyond 9 pm in the summer, having a late evening meal can be tempting. But before you delay your dinner time, take note that the 2022 Sleep in America Poll , conducted by the National Sleep Foundation, revealed that having regular meal times during the day has a significant positive impact on your sleep.
This is, the National Sleep Foundation explains, because of how your meal times are directly linked to your body's internal sleep and wake mechanism, since they "can act as an important cue for the circadian rhythm." Eating at different times on a day or missing meals "can negatively influence the ability to maintain sleep and wake schedules, especially if meals are eaten too close to bedtime."
Get instant access to breaking news, the hottest reviews, great deals and helpful tips.
Which leads us to why it's better to avoid late-night summer meals.
Some foods can increase the body's core temperature (which can suppress the release of melatonin) when metabolized, and the overall process of metabolizing food will also raise your body temperature. Eating late can also cause other issues like bloating, indigestion or heartburn which can keep you awake and sabotage your sleep.
It might be tempting to stay awake to see the sunset on the longest day of the year, and perhaps even longer, but this may also lead to having a bad night's sleep.
That's because disrupting your normal bedtime will throw off your sleep schedule. Sticking to regular sleep and wake up times helps regulate your circadian rhythm, leading to better quality sleep (and sleep quality is equally as important as quantity), can help you avoid daytime sleepiness and even lead to better health outcomes.
While you may be able to pay back the sleep debt you get from a late night on summer solstice during the same weekend, a consistent schedule will help you get a good night's rest, every night.
External distractions like light can hinder sleep on any night of the year, but obviously there's going to be more daylight in the evening during the summer solstice. Even if you're inside, sunlight seeping into your bedroom can still confuse your brain into thinking you need to be active.
Investing in blackout curtains or an eye mask are great tool to avoid this, especially if you're a light sleeper. Sticking to a regular nighttime routine will also help you winddown in time for bed, even if it's still bright outside.
Looking for more sleep accessories to help you fall asleep faster and get restful sleep? Scroll down for our top picks...
1. Kitsch Satin Sleep Mask: was from $17.99 from $14.39 at AmazonGetting a soft to touch sleep mask is a more affordable alternative to installing blackout curtains in your bedroom. This one from Kitsch promises to block out light, and includes light padding for extra comfort, perfect for restful sleep. You can now grab this at 20% off, which drops the MSRP from $17.99 to $14.39 on Amazon.
2. QWH Silicone Ear Plugs for Sleeping: was from $29.99 now from $9.98 at AmazonAmbient noise is yet another distraction to sleep, which is more likely to present when the days are longer and people are up and about later. A simple solution is to pop in a pair of ear plugs. The QWH reusable ear plugs boast noise reduction up to 30dB, are crafted from lightweight silicone and are available in four sizes (XS, S, M and L). These currently have 67% off, which brings down the MSRP from $29.99 to just $9.98 at Amazon.
3. YnM Breathable Weighted Blanket: twin in 15lb $34.99 at AmazonDeep pressure therapy has been proven to reduce anxiety and promote rest and relaxation. The YnM breathable weighted blanket will help you achieve this thanks to its glass beads and fiber fill, while our reviewer was surprised to find it breathable and the cover cool-to-touch, which is great for summer nights. You can now find a gray, 15lb weight in a twin size for $34.99 on Amazon. There are cheaper kids' sizes available, and prices vary for other sizes and weights.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


NBC News
an hour ago
- NBC News
Texas woman sues Marine, claiming he spiked her drink with abortion pills
A Texas woman is suing a U.S. Marine, alleging he spiked her drink with nearly a dozen abortion pills, killing their unborn child, after she rebuffed his repeated requests to 'get rid of it,' according to a wrongful death lawsuit filed in federal court Monday. Liana Davis alleges Christopher Cooprider secretly dissolved at least 10 abortion pills into a cup of hot chocolate that he prepared for her April 5 and then left the house and stopped responding as she profusely bled, the suit says. Cooprider, 34, declined to comment Monday. The lawsuit, filed in the U.S. District Court for the Southern District of Texas, contains several purported text messages the pair exchanged for weeks, beginning Jan. 31, when Davis asked Cooprider for his input in case she is confirmed to be pregnant. Cooprider said he 'would like to get rid of it,' the texts show, saying the two were 'not in love' or together and that it would be 'messed up to bring a child into the world without both parents raising them.' When Cooprider reiterated his desire for Davis to 'get rid of it' after her pregnancy test came back positive days later, she asked him to use a different phrase. 'Every time you say 'get rid of it' it's like an electric shock,' she wrote, according to the lawsuit. 'I literally feel like I'm going down the steepest hill on a roller coaster when I read that.' The following text messages allegedly show Cooprider telling Davis, without her approval, that he would order abortion pills online. The pills were purchased from Aid Access, an online service that ships abortion pills to Americans from abroad, according to the lawsuit. Aid Access, and Dr. Rebecca Gomperts, a Dutch physician who runs it, are also listed as defendants in the lawsuit. They did not immediately return requests for comment. For the next several weeks, Cooprider was unable to convince Davis to get an abortion, and the text messages grew more contentious. On March 6, Cooprider called the baby a 'thing' and blamed Davis for her 'psycho mentality' that he said caused her ongoing divorce. The lawsuit says Cooprider also threatened to testify against Davis in her divorce proceeding and bid to have custody of her three children. At the end of March, Cooprider texted that he wanted to 'abort this monstrosity of a situation' and said he felt 'trapped' by the situation. But on April 2, Cooprider appeared to change his tone in text messages to Davis. He proposed making them 'some warm relaxing tea' in what they could call a 'trust building night,' according to screenshots shared in the lawsuit. Davis, who was eight weeks pregnant, accepted. When the two met up at Davis' Corpus Christi residence on the night of April 5, Cooprider handed her a cup of hot chocolate shortly before midnight, according to the lawsuit. Within 30 minutes of drinking it, the suit says, Davis began hemorrhaging and cramping. Davis knew she had to go to the emergency room, but she knew she could not leave her three children who were sleeping upstairs, the suit said. They came up with a plan for Cooprider to pick up Davis' mother, who lived nearby, so she could watch the children while Cooprider took Davis to the hospital. But once Cooprider left the house, he became unreachable, according to the lawsuit. 'I am gushing blood. Please hurry,' Davis texted him around 12:30 a.m. Davis's mother took an Uber ride to her daughter's house around 1 a.m. Around that time, Cooprider apologized and said he had to catch a flight the next day, the suit said. A neighbor drove Davis to the hospital, where her unborn baby, whom she had named Joy, did not survive. Back home, Davis said she found the opened box of abortion pills and a pill bottle, which she turned over to the Corpus Christi police, according to the lawsuit. The suit claims Cooprider mixed 10 misoprostol pills into the hot chocolate. The Corpus Christi Police Department said there are no active investigations involving Cooprider.
Yahoo
an hour ago
- Yahoo
Mass. woman raises money on GoFundMe after bat flies into her mouth, prompting $21K medical bill
A Massachusetts woman who recently lost her job and was left with a $21,000 medical bill after a bat flew into her mouth during a trip to Arizona has set up a GoFundMe to support herself. Westford resident Erica Kahn previously worked as a biomedical engineer, she wrote in her fundraiser campaign's description. She lost her job last summer and thought she would have a new job in a few months. Kahn signed up for new coverage, but she did not know it had a 30-day waiting period, WCVB-TV reported. 'Since I was fun-employed, I traveled to Horseshoe Bend in Arizona, where my dad and I took some long exposure photos of the beautiful landscape at night,' Kahn wrote on GoFundMe. While she was taking photos, she saw bats flying nearby, The Arizona Republic reported. One flew into her mouth. 'As I was screaming, part of the bat unfortunately went in my mouth (fun fact, they taste earthy and a little sweet!),' Kahn wrote on GoFundMe. Kahn's father, who works as a doctor, told her to go to the emergency room for rabies shots, she wrote. Kahn had lost her $650-per-month COBRA plan 11 days earlier. So while she was in the emergency room, she tried to sign up through Innovative Partners Her claims were denied and she received her three shots and four rabies vaccine doses from other hospitals, Kahn wrote. The medical bills totaled $20,749.29. 'It's mentally pretty stressful to think about that sum of money,' Kahn told Republic. Kahn set up the GoFundMe with a goal of donating half of the proceeds to the United Nations Children's Fund (UNICEF) to 'help provide healthcare to families in need,' she wrote. Her goal is to receive $12,000. 'I wish our healthcare system wasn't so broken in the United States,' she continued. 'I believe life-saving medical care is a fundamental human right and it's depressing that Americans can only turn to GoFundMe instead of a federally protected safety net. I made a mistake by choosing not to pay for COBRA, but the cost of these seven shots is pretty extreme. Also, I still believe that bats are an important part of our ecosystem and I feel no ill will toward them! Protect the bats!' The campaign has received 29 donations, including eight $50 donations. 'As Michael Scott said in 'The Office,' 'Myth: three Americans every year die from rabies. Fact: four Americans every year die from rabies,'' Kahn wrote at the end of her campaign. More health-related stories Mass. beach closures: These are the beaches closed on Tuesday, Aug. 5 Worcester health and human services commissioner to retire after 10 years Mass. beach closures: Almost 40 beaches closed on Monday, Aug. 4 Read the original article on MassLive. Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression
This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the Designation granted in 2017 for bipolar depression alone The Designation includes an FDA determination that NRX-100 has the potential to address an unmet need, based on FDA's assessment of the data submitted Determination of "unmet need" is a requirement for a Commissioner's National Priority Voucher (CNPV) program. Suicide is a public health crisis. Approximately 13 million adults seriously consider suicide each year, according to the CDC, 3.7 million make a plan to commit suicide. An American dies from suicide every 11 minutes. Active-duty personnel, veterans, and first responders have a four-fold higher risk of suicide. WILMINGTON, Del., Aug. 11, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced US Food and Drug Administration (FDA) has granted Fast Track designation to NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. This designation for NRX-100 as a standalone drug is a 10-fold expansion of the addressable population for NRX-100, compared to the designation granted in 2017 for NRX-100 in combination with NRX-101 (DCS/lurasidone) for treatment of Suicidal Bipolar Depression. In granting the Fast Track designation, FDA made the determination that NRX-100 has the potential to address an unmet medical need, based on an assessment of the preliminary data contained in the Fast Track designation request. This determination of unmet medical need aligns with the eligibility requirements for the Commissioner's National Priority Voucher Program (CNPV)i and for the FDA's Accelerated Approval The Company has applied for a CNPV, which has the potential to substantially shorten the review cycle for NRX-100. Several well-controlled trials submitted to FDA in support of Fast Track Designation demonstrated a clinically meaningful and statistically significant reduction of suicidal ideation. In a Columbia University study licensed by NRx, suicidal patients treated with intravenous ketamine demonstrated a 55% response (i.e. 50% reduction in suicidality) compared to a 30% response to active comparator (P<.02).iii In a trial sponsored by the Government of France and licensed by NRx, 63% of patients achieved full remission from suicidal ideation in three days compared to 31% of those who received placebo (P<.001). This effect has not been proven with intranasal administration of "We thank FDA for its thoughtful review of our Fast Track designation request, and believe this regulatory determination is a significant step forward in our goal to address the national crisis of suicide among soldiers, first responders, veterans, and civilians alike." said Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals. "Large-scale government-supported trials have demonstrated a robust and statistically significant reduction in suicidal ideation and depression with administration of ketamine. This drug was also proven to be non-inferior to electroshock therapy in treating depression without the negative side effects of ECT. We look forward to working closely with the FDA in our quest to Bring Hope to Life." Under the terms of the Fast Track program, NRx will be posting an expanded access policy for NRX-100 in the next two weeks and seeking a meeting with FDA leadership to finalize the data to be submitted under the Accelerated Approval / CNPV application. In addition to the benefits above, Fast Track Designation also grants enhanced communication with the FDA, as well as potential Priority Review and Rolling Review. NRX-100 in Suicidal Ideation in Patients with Depression, Including Bipolar Depression According to the CDC, approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – is designed to help address this national crisis. NRx will be submitting patient-level data from controlled clinical trials that demonstrate ketamine to be superior to both a placebo and an active comparator, as well as either non-inferior or superior to electroshock therapy in treating various forms of depression, including patients with active suicidal ideation. Although ketamine in various forms is increasingly used to treat depression and related disorders, it is currently only approved by FDA only for use as an anesthetic and, therefore, not reimbursed by most insurance carriers for treatment of suicidality or depression. Intravenous ketamine is reimbursed by the Department of Veterans Affairs and the Department of Defense for its beneficiaries. By applying for FDA labeling for NRX-100 to treat suicidal depression, the Company hopes to make this potentially life-saving therapy available to all Americans, not just those who are able to pay out of pocket. The Company has previously filed full Chemical Manufacturing and Controls (CMC) information for NRX-100 with FDA and has reported stability and sterility data sufficient to anticipate three-year room temperature shelf life for preservative-free ketamine. Having completed this Fast Track Designation, NRx is now filing draft labeling for NRX-100 to comply with the CNPV requirement. NRX-100 is the first preservative-free presentation of ketamine to be filed with FDA. Currently available product, primarily of foreign manufacture, contains a known toxic preservative, Benzethonium Chloride (BZT) that is not Generally Recognized as Safe (GRAS) and is not allowed by FDA to be used in hand cleaners and topical antiseptics. NRx demonstrated long term stability and sterility with its patented preservative-free formulation of NRX-100. The Company has additionally filed a Citizen Petition seeking to have BZT removed from all intravenous ketamine products. The Company has instituted US-based high-volume manufacture of sterile, preservative-free ketamine. Regarding Fast Track designation, FDA's website states: A drug that receives Fast Track designation is eligible for some or all of the following: More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval. More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met. Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA. NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. References i Grunebaum, et al. Ketamine for rapid reduction of suicidal thoughts… Am J Psychiatry 2018;175: Abbar, et al. Ketamine for the acute treatment of severe suicidal ideation… BMJ 2021;167:194-203 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy Chief Business Officer, NRx Pharmaceuticals mduffy@ Brian Korb Managing Partner (917) 653-5122 View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data